Key points are not available for this paper at this time.
The incorporation of artificial intelligence (AI) is revolutionizing patient-clinician interactions and decision-making processes in the dynamic field of clinical trials. AI-driven chatbots, using progress in natural language processing (NLP) and machine learning, are becoming essential mechanisms for improving these interactions. The present study investigates the use of artificial intelligence chatbots in clinical trials, with a specific emphasis on their capacity to enhance patient involvement, optimize data gathering, and facilitate clinical decision-making. Artificial intelligence chatbots have many advantages within the realm of clinical studies. They offer round-the-clock assistance, enabling patients to get information and resolve issues outside of standard office hours. Consistent availability of this service facilitates effective communication between patients and clinical personnel, hence enhancing patient satisfaction and compliance with trial guidelines. The delivery of personalized information on trial processes, medication regimens, and side effects by chatbots might effectively decrease the cognitive burden on patients and augment their comprehension of the trial process.
Voola et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: